Home / Organizations / Commonwealth Serum Laboratories

Commonwealth Serum Laboratories

The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. CSL Limited was then incorporated in 1991 and listed on the Australian Stock Exchange in 1994. CSL Limited is now a global specialty biotechnology company, headquartered in Parkville, Victoria, an inner suburb of Melbourne, that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions. Today CSL has major facilities in Australia, Germany, Switzerland and the US, employs over 13,000 employees working in 27 countries.

In 2000 CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the 2nd Australian public company to have reached a share price of over $100 per share. CSL is a leading manufacturer in a US$7.5 billion plasma industry. CSL is also a major manufacturer in a US$2 billion influenza industry, with 40 years manufacturing experience and sales spanning 27 countries around the globe.

Product Portfolio:

  • Blood plasma derivatives
  • Vaccines
  • Antivenom
  • Cell Culture Reagents

Company Information

Type Public
Traded as ASX: CSL
Industry Biotechnology
Founded 916 (Federal government department), 1994 (privatised)
Founder NA
Headquarters Parkville, Melbourne, Victoria
Key people Paul Perreault (CEO)
Products blood plasma, vaccines, antivenom, other laboratory and medical products
Revenue USD$5.000 billion (2013)
Net income USD$1,216 million (2013)
Number of employees 13,000
Subsidiaries NA
Website www.csl.com.au

Check Also

Teva Pharmaceutical Industries Ltd.

The company known today as Teva Pharmaceutical Industries Ltd. was established in Jerusalem in 1901. It …